Penicillamine Veterinary Grade API, the D-enantiomer of 3,3-dimethylcysteine (CAS 52-67-5; molecular formula C5H11NO2S; relative molecular mass 149.21 g/mol), is supplied as a white or almost white crystalline powder for formulation into oral tablets, hard capsules, injectable solutions, oral powders, granules, premixes, and liquid preparations. The veterinary grade is distinguished from general chemical reagent grade by compendial identity and purity controls aligned to the current USP Penicillamine monograph and by supplementary controls relevant to multi-species dosage forms. Release testing includes infrared absorption spectrophotometry against USP Penicillamine RS, specific rotation measurement in the negative range for the D-enantiomer, and an assay acceptance range of 97.0–102.0% calculated on the dried basis. Loss on drying, residue on ignition, penicillamine disulfide-related impurity content, elemental impurities under USP 232/233, residual solvents under USP 467, and microbial enumeration under USP 61/62 are controlled according to current monographs. Manufacture is conducted under ICH Q7 for active pharmaceutical ingredients, with batch documentation that supports use under 21 CFR 530 for extralabel veterinary use in the United States. The API is not supplied as sterile material unless specifically designated for injection manufacturing.

The free thiol group has an acid dissociation constant near 7.9, so chelation of copper involves the thiolate anion and competes with protonation in gastric fluid. The compound is freely soluble in water, slightly soluble in ethanol, and practically insoluble in chloroform. Aqueous solubility and pH control influence the choice of buffer for injectables; formulations below pH 5.0 reduce oxidation to penicillamine disulfide by limiting thiolate formation, whereas neutral pH accelerates oxidation and requires nitrogen overlay. The crystalline powder is hygroscopic enough that pre-drying is required at relative humidity above 60% before direct compression. Exposure to open air and trace metal surfaces should be avoided.

Manufacturer model or grade codes distinguish the standard milled, micronized, granulated, and injection-grade variants; suffixes such as M, X, G, and I in the certificate of analysis designate milling intensity and environmental control level. The model code is not a substitute for the full pharmacopeial specification and must be cross-referenced against the batch-specific certificate of analysis.

What Limits Batch-to-Batch Homogeneity in Veterinary Premix Granulation?

Penicillamine base exhibits a crystalline habit that can segregate when blended as a cohesive, low-bulk-density powder. In production-scale double-cone or bin blenders, unmodified API with a particle size span greater than 2.0 and median particle size above 150 µm may stratify in low-dose premixes because the active particle size distribution does not match the excipient distribution. Formulators address this by roller compaction or wet granulation in a high-shear granulator before drying in a fluid-bed dryer. Process parameters such as inlet air temperature 45–60 °C, product temperature below 40 °C, and final loss on drying 1.0–2.5% are typical for granulated penicillamine formulations; however, the exact window must be confirmed because of the thiol group’s sensitivity to oxidative degradation. A twin-screw extruder with an L/D ratio of 25:1 to 40:1 is used for some dry-granulation alternatives, with barrel temperature not exceeding 35 °C to avoid disulfide formation. Blend uniformity is assessed by sampling at 10 or more locations using high-performance liquid chromatography with UV detection at approximately 210 nm; relative standard deviation targets below 5.0% are commonly applied for oral solid dosage forms. Published data for this specific configuration is limited, so the acceptance range is set through process qualification rather than compendial monograph.

Direct compression after dry granulation is preferred when the API fraction is below 10 wt%, because the API’s low tapped density and poor flowability reduce die filling at higher drug loads. Microcrystalline cellulose, dibasic calcium phosphate dihydrate, or lactose monohydrate carriers with particle size distribution d10 30–50 µm, d50 90–130 µm, and d90 180–220 µm can be matched to the granulated API to minimize segregation. The ejection force and tablet hardness profiles on a rotary tablet press with a force feeder are monitored; friability is controlled to ≤1.0% per USP 1216 and disintegration to ≤15 min for uncoated tablets per USP 701. Capsule filling of low-dose products requires tight control of powder flow; slugging or dry granulation reduces the bulk volume variability that otherwise causes weight variation and content uniformity failures under USP 905.

Analytical release of finished veterinary products containing penicillamine typically uses ion-pair reversed-phase HPLC with a phosphate buffer and acetonitrile mobile phase at pH 3.0, with UV detection at 210 nm; this method separates penicillamine from penicillamine disulfide and from forced-degradation products. Method validation follows VICH GL2 for specificity, linearity, accuracy, and precision; the reporting threshold for impurities is commonly 0.05%. Dissolution testing for tablets follows USP 711 using 0.1 N hydrochloric acid at 37 °C with a paddle speed of 50 rpm; however, published monograph-specific dissolution data for veterinary penicillamine tablets is limited.

Wet granulation with aqueous binder must be evaluated because penicillamine can oxidize in the presence of free water. Aqueous granulation should be completed at low product temperature and dried promptly; alcohol-based granulation is used when water exposure must be minimized. The granulation endpoint is often determined by impeller power draw or torque-rheometry rather than fixed time alone. Drying in a fluid-bed dryer with inlet air dew point below −20 °C reduces moisture uptake and oxidative degradation. Milling after drying through a conical mill with a screen aperture of 0.8–1.2 mm yields granules suitable for tablet compression and for packaging into sachets.

Residual Solvent and Elemental Impurity Control in Multi-Species Formulations

Veterinary API release must address species differences in metabolism and permissible impurity burden. For oral powders and premixes intended for food-producing animals, the elemental impurity risk assessment follows VICH GL18 and USP 232/233, with particular attention to palladium, lead, arsenic, and cadmium introduced during asymmetric synthesis or downstream hydrogenation steps. Residual solvent testing under USP 467 may be performed by headspace gas chromatography with flame ionization detection; class 2 residual solvents are reported at limits derived from the permitted daily exposure scaled to the target species. The table lists standard release parameters for a veterinary-grade D-penicillamine API used in non-sterile oral dosage forms.

Packaging for non-sterile API is normally double low-density polyethylene liners inside an aluminum-laminated fiber drum. The retest period is established from long-term data under ICH/VICH storage conditions, commonly 24 months at 25 °C/60% RH; if storage exceeds 30 °C/65% RH, forced degradation data should be reviewed and a reduced retest period assigned.

When Injection-Grade API Requires Endotoxin and Subvisible Particulate Control

Penicillamine injection solutions are not stable for long-term storage as simple aqueous solutions because the free thiol oxidizes to penicillamine disulfide in the presence of dissolved oxygen and trace metals. Manufacturing therefore uses water for injection sparged with nitrogen, type I borosilicate glass vials, and elastomeric closures with low oxygen transmission; fill lines may be purged with nitrogen to maintain residual oxygen below 2 ppm in the headspace. The bacterial endotoxin limit is derived from the maximum intended dose; for a 10 mg/kg parenteral dose in dogs, a limit of ≤0.25 EU/mg is commonly applied under USP 85, but the final product monograph may specify a stricter value if the dosing interval is prolonged. Subvisible particulate testing follows USP 788 Method 1 for products with labelled volume ≤100 mL; the acceptance criteria are ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm. Terminal sterilization by moist heat is generally unsuitable because of the thiol’s thermal sensitivity in solution; manufacture is therefore by aseptic filtration using a 0.22 µm membrane filter, with filter compatibility testing to confirm that the API does not bind to the polyvinylidene difluoride or polyethersulfone membrane.

Oral solutions and extemporaneous suspensions prepared from bulk API require compounding stability data. In aqueous vehicles, the pH is adjusted to 3.0–5.0 to reduce oxidation rate, and disodium edetate may be added at 0.01–0.1% w/v. Storage at 2–8 °C in amber glass minimizes disulfide formation; however, the solution should be evaluated for visible precipitation and assay loss after 7–14 days because the thiol group can form mixed disulfides with cysteine or glutathione from the vehicle. Published data for this specific configuration is limited.

Comparing Milled Penicillamine with Trientine Salts in Canine Protocols

Penicillamine differs from trientine dihydrochloride and zinc acetate in both mechanism and clinical use. Penicillamine mobilizes hepatic copper by forming soluble penicillamine-copper complexes that are excreted in urine; trientine acts as a copper chelator with a polyamine structure that may be tolerated when penicillamine causes gastrointestinal signs or immune-mediated reactions. The initial canine dose in copper-associated hepatopathy is commonly reported as 10–15 mg/kg by mouth every 12 h, with food; efficacy is monitored by serial hepatic copper quantification from liver biopsy because serum copper and ceruloplasmin do not reflect hepatic stores. For cystinuria, penicillamine dissolves cystine stones through disulfide exchange; the therapeutic dose must be adjusted to maintain urine pH above 7.0 and urine specific gravity below 1.030. The selection between penicillamine and trientine depends on adverse-effect profile, availability, cost, and species-specific licensing status. In the United States, veterinary use of penicillamine is often through compounded or extra-label use under the Animal Medicinal Drug Use Clarification Act; the API is supplied as a veterinary grade to support current good manufacturing practice-compliant compounding and licensed product development.

Unlike zinc acetate, which reduces intestinal copper absorption rather than causing urinary excretion, penicillamine is a systemic chelator; therefore hepatic copper burdens above 2000 µg/g dry weight in dogs may require initial penicillamine therapy rather than zinc monotherapy. Only the D-enantiomer is used; L-penicillamine is not considered safe for therapeutic administration. Veterinary grade material must be separated from industrial-grade D-penicillamine used in asymmetric synthesis, because reagent material may contain residual organic solvents and metal catalysts that are not acceptable for injection or oral use.

Premixes for food-producing animals may contain penicillamine at low mass fraction, such as 0.1–1.0%; in these cases a stepwise geometric dilution is required. The first pre-blend is typically prepared at 1:5 or 1:10 active-to-carrier ratio using a high-shear blender operating at 25–50 rpm for 5–10 min. Subsequent dilution into final feed carriers is performed in a double-ribbon blender or drum blender with fill volume 50–75%. Sampling for content uniformity uses stratified thief sampling at 10 locations. A relative standard deviation ≤5.0% is required before release for feed mixing.

Incompatibility data must be included in the API technical file. Penicillamine is incompatible with strong oxidizing agents, aldehydes, and trace metal ions that catalyze disulfide formation. The dry powder should not be blended with basic excipients that raise microenvironmental pH above 7.0 without dry granulation or coating, because alkaline pH accelerates thiol oxidation. Mannitol is preferred over reducing sugars in oral powder formulations because reducing carbohydrates can form Maillard-type adducts with the primary amine. The API should be stored in sealed aluminum-laminated drums under nitrogen, protected from light and moisture. At relative humidity above 60%, re-test for loss on drying and penicillamine disulfide before use. These operational boundaries apply to the veterinary grade unless a specific co-processed grade is supported by stability data.